Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in newly diagnosed chronic-phase CML
NL-OMON36686Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Complete molecular response rate at 18 months. Started Jun 2010; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON36686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36686.